—
C+
C+ The full Closelook — membership. Open the C+ overview

Teva Pharma Industries Ltd ADR (TEVA) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Teva Pharma Industries Ltd ADR

TEVA in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Teva makes and sells generic medicines across many dosage forms alongside branded treatments for the nervous system, respiratory illness and cancer, and supplies active ingredients and contract manufacturing to other drugmakers. It licenses products to other pharmaceutical firms and has agreements with partners such as Sanofi and Alvotech. It is headquartered in Tel Aviv and lists in the United States as an ADR, a certificate that lets US investors hold foreign shares.
Where it sits in the stack
Teva has no seat in our index, Rubin, which tracks the AI build-out; it belongs to the diary's Healthcare sleeve, the part of our universe covering scored drugmakers rather than compute or chip layers.
Who it is priced against
Closelook's peer group places it with other scored Healthcare names based in the US, among them Regeneron, Vertex and BeiGene; the market also compares it with fellow generics maker Viatris.
Why Closelook tracks it
Teva carries a Closelook score built from several modules; momentum reads strongest, quality reads weakest. It holds no seat in our index and has not yet appeared in the diary's editions or quotes.
What the diary watches
The diary watches whether branded launches such as AJOVY and UZEDY keep offsetting pricing pressure in the generics business, since that balance feeds the quality module's read.

Teva Pharma Industries Ltd ADR (TEVA) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 44/100 composite (momentum 79, quality 48, valuation 43) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for TEVA, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 7 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against TEVA on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What TEVA pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +3.7% in FY2025 157 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Teva Pharma Industries Ltd ADR (TEVA)?

Teva Pharma Industries Ltd ADR trades as TEVA on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is TEVA in a Closelook index?

Not currently — Teva Pharma Industries Ltd ADR is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is Teva Pharma Industries Ltd ADR's Closelook composite score?

44 out of 100, with momentum 79, quality 48 and valuation 43 sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does TEVA trade against its moving averages?

Uptrend stack intact: Trades +10.9% vs the 50-day and +18.8% vs the 200-day average, 3.1% below the 52-week high and +117% off the 52-week low. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Teva Pharma Industries Ltd ADR do?

Teva makes and sells generic medicines across many dosage forms alongside branded treatments for the nervous system, respiratory illness and cancer, and supplies active ingredients and contract manufacturing to other drugmakers. It licenses products to other pharmaceutical firms and has agreements with partners such as Sanofi and Alvotech. It is headquartered in Tel Aviv and lists in the United States as an ADR, a certificate that lets US investors hold foreign shares. Closelook's peer group places it with other scored Healthcare names based in the US, among them Regeneron, Vertex and BeiGene; the market also compares it with fellow generics maker Viatris.

Where does Teva Pharma Industries Ltd ADR sit in the AI build-out?

Teva has no seat in our index, Rubin, which tracks the AI build-out; it belongs to the diary's Healthcare sleeve, the part of our universe covering scored drugmakers rather than compute or chip layers. Teva carries a Closelook score built from several modules; momentum reads strongest, quality reads weakest. It holds no seat in our index and has not yet appeared in the diary's editions or quotes.

Does Teva Pharma Industries Ltd ADR pay a dividend?

No cash distribution shows in Teva Pharma Industries Ltd ADR’s price series over the last three years. The share count rose 3.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for TEVA, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.